Clinical Trials Logo

Filter by:
NCT ID: NCT04813159 Not yet recruiting - STEMI Clinical Trials

Remote Ischaemic Conditioning in STEMI Patients in Sub-Saharan AFRICA

Start date: May 2021
Phase: N/A
Study type: Interventional

The RIC-AFRICA study is a sub-Saharan African prospective, multi-centre, randomised, sham-controlled, clinical trial of 1200 ST-segment elevation myocardial infarction (STEMI) patients undergoing predominantly thrombolytic therapy in 18 sites across South Africa, Kenya, Sudan and Uganda. The purpose of the study is to determine whether Remote Ischaemic Conditioning (RIC) can reduce the rates of all-cause death and early post-myocardial heart failure at 30-days in STEMI patients treated predominantly with thrombolytic therapy.

NCT ID: NCT04475471 Recruiting - Clinical trials for Cardiovascular Diseases

WORLD HEART FEDERATION (WHF) COVID-19 and Cardiovascular Disease Survey

Start date: June 11, 2020
Study type: Observational

A global study for a better understanding of the cardiovascular conditions that increase the risk of developing severe COVID-19, and a better characterization of cardiovascular complications in hospitalized patients with COVID-19.

NCT ID: NCT04401969 Completed - Mycetoma Clinical Trials

Tissue Microenvironment Signatures of the Mycetoma Granuloma

Start date: March 7, 2019
Study type: Observational

Mycetoma is the most neglected of the neglected tropical diseases. It is caused by certain fungi or bacteria. It is endemic in many tropical and subtropical regions and Sudan seems to be the mycetoma homeland. This chronic subcutaneous destructive and disabling inflammatory disease has many serious medical and socio-economic impacts on patients, community and health authorities. This work may suggest new therapeutic options for mycetoma that target the inflammatory pathogenic pathway and hence help in designing universal treatment options for mycetoma patients. Two overlapping aims were investigated in this project to advance our overall goals: 1. Profiling the immune/inflammatory signatures in the tissue microenvironment of fungus-induced mycetoma lesions 2. Profiling the immune/inflammatory signatures in the tissue microenvironment of bacteria-induced mycetoma lesions.

NCT ID: NCT04381871 Not yet recruiting - COVID 19 Clinical Trials

Potential Role of Gum Arabic as Immunomodulatory Agent Among COVID 19 Patients

Start date: June 1, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

To study the efficacy of Gum Arabic as an immuno modulator and anti-inflammatory agent among COVID 19 seropositive patients..Half of participants will receive Gum Arabic and the other half will receive placebo

NCT ID: NCT04215380 Enrolling by invitation - Clinical trials for Polycystic Ovary Syndrome

Effects of Gum Arabic Ingestion on Hormonal and Metabolic Changes in Patients With Polycystic Ovary Syndrome

Start date: January 25, 2020
Phase: N/A
Study type: Interventional

To assess the effects on hormonal and metabolic changes in the PCOs patients after ingestion of Arabic gum

NCT ID: NCT04207645 Terminated - Acute Appendicitis Clinical Trials

Modification and Validation of the RIPASA Score for Diagnosis of Acute Appendicitis

Start date: November 1, 2019
Study type: Observational

Purpose: The diagnostic approach of patients with acute appendicitis (AA) remains debated. A number of clinical prediction rules (CPRs) exist for diagnosis of AA with variable sensitivity, specificity, and diagnostic accuracy, in different ethnic populations. Among these, the Raja Isteri Pengiran Anak Saleha Appendicitis (RIPASA) score was shown to have a high sensitivity though with a poor specificity. The aim of this study is to modify and validate the RIPASA score in 4 distinct ethnic groups, and to compare the performance of the new score to the original RIPASA and Alvarado scores. Methods: This multicenter, international prospective observational study will be conducted in 6 countries, and will include all eligible patients referred to surgical specialists with acute right iliac fossa pain or suspected AA in the participating centres. Patients will be categorized into 4 ethnic groups based on the country of origin. The modified RIPASA score will be developed in one ethnic group, and along with the original RIPASA and Alvarado scores, will be externally validated in the other 3 ethnic groups. Management of patients will be prospectively evaluated in a standardized manner. The focus of the analysis will be on the performance of the 3 CPRs in different ethnic and gender groups using receiver operating characteristic curve analyses. Discussion: We expect this study to develop a CPR that can assist surgeons and surgical residents to early identify patients with AA in the busy clinical and low-resource settings, and to optimize the diagnostic value of the RIPASA and Alvarado scores in different ethnic and gender groups.

NCT ID: NCT04191213 Recruiting - Clinical trials for Sickle Cell Anemia in Children

Gum Arabic as Anti-oxidant, Anti-inflammatory and Fetal Hemoglobin Inducing Agent in Sickle Cell Anemia Patients

Start date: February 15, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

To study the efficacy of Gum Arabic as an anti-oxidant, anti-inflammatory and Fetal Hemoglobin-inducing agent among Sickle Cell Disease children. Half of participants will receive Gum Arabic and the other half will receive placebo

NCT ID: NCT03969134 Recruiting - Clinical trials for Leishmaniasis, Cutaneous

A Study to Assess the Safety, Efficacy and Immunogenicity of Leishmania Vaccine ChAd63-KH in PKDL

Start date: April 6, 2020
Phase: Phase 2
Study type: Interventional

This trial is designed to assess the therapeutic efficacy and safety of CHAd63-KH, a new candidate Leishmania vaccine, in patients with persistent PKDL. 100 participants will be randomly assigned (50 participants in each arm) to receive placebo or ChAd63-KH 7.5 x10(10)vp. Doses will be administered at a single time point.

NCT ID: NCT03789708 Active, not recruiting - Clinical trials for Kidney Failure, Chronic

Effects of Gum Arabic Supplementation in Hemodialysis Patients

Start date: November 1, 2018
Phase: N/A
Study type: Interventional

Gum Arabic is a naturally produced gummy exudate from Acacia Senegal tree. It's a complex polysaccharide with proven prebiotic properties. Through its effect on intestinal bacteria, it's expected to reduce systemic levels of toxic bacterial metabolites and reduce inflammatory markers.By increasing fecal bacteria mass it's also expected to reduce blood urea level. These changes are potentially beneficial to hemodialysis patients who suffer from disturbed intestinal flora and a chronic inflammatory status. The investigators hypothesize that supplementing the diet of hemodialysis patients with Gum Arabic for four weeks would reduce inflammatory markers, increase total anti-oxidant capacity and reduce blood urea concentration.

NCT ID: NCT03789006 Recruiting - Clinical trials for Kidney Transplant Rejection

Antithymocyte Globulin and Azathioprine Versus Basiliximab and Mycophenolate Mofetil in Living Donor Kidney Transplantation

Start date: March 21, 2018
Phase: Phase 4
Study type: Interventional

Kidney transplantation is the best available treatment option for patients with end stage renal disease. However, kidney transplantation requires life-long use of immunosuppressive medication. Because of the high cost of these medications we need to carefully evaluate the cost-effectiveness of each drug regimen, especially in low-middle income countries. The objective of this clinical trial is to compare the efficiency and cost of two immunosuppressive protocols after living donor kidney transplantation: (1) antithymocyte globulin, tacrolimus, azathioprine and prednisolone versus (2) basiliximab, tacrolimus, mycophenolate mofetil and prednisolone.